{"id":"https://openalex.org/W3083326487","doi":"https://doi.org/10.1158/1538-7445.am2020-2223","title":"Abstract 2223: A novel protein nanoparticle antigen delivery platform combined with checkpoint inhibition has curative efficacy in the aggressive B16-F10 melanoma model","display_name":"Abstract 2223: A novel protein nanoparticle antigen delivery platform combined with checkpoint inhibition has curative efficacy in the aggressive B16-F10 melanoma model","publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3083326487","doi":"https://doi.org/10.1158/1538-7445.am2020-2223","mag":"3083326487"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-2223","doi":"https://doi.org/10.1158/1538-7445.am2020-2223","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-2223","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006371204","display_name":"Jo Anne Tucker","orcid":"https://orcid.org/0000-0003-4410-4269","observed_orcids":["https://orcid.org/0000-0003-4410-4269"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jo Anne Tucker","raw_affiliation_strings":["1University of California, Irvine, Irvine, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of California, Irvine, Irvine, CA;","institution_ids":["https://openalex.org/I204250578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020894583","display_name":"Medea Neek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Medea Neek","raw_affiliation_strings":["2Stanford University, Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Stanford University, Palo Alto, CA","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054570777","display_name":"Szu\u2010Wen Wang","orcid":"https://orcid.org/0000-0001-7398-0220","observed_orcids":["https://orcid.org/0000-0001-7398-0220","https://orcid.org/0000-0002-1240-6126"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Szu-Wen Wang","raw_affiliation_strings":["1University of California, Irvine, Irvine, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of California, Irvine, Irvine, CA;","institution_ids":["https://openalex.org/I204250578"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086973652","display_name":"Edward L. Nelson","orcid":"https://orcid.org/0000-0001-7887-032X","observed_orcids":["https://orcid.org/0000-0001-7887-032X"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward L. Nelson","raw_affiliation_strings":["1University of California, Irvine, Irvine, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of California, Irvine, Irvine, CA;","institution_ids":["https://openalex.org/I204250578"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"2223","last_page":"2223"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antigen-delivery","display_name":"antigen delivery","score":0.8220000267028809},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.722000002861023},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8840000033378601},{"id":"https://openalex.org/keywords/b16f10-melanoma","display_name":"B16F10 melanoma","score":0.984000027179718},{"id":"https://openalex.org/keywords/gp100","display_name":"gp100","score":0.8999999761581421},{"id":"https://openalex.org/keywords/cpg-adjuvant","display_name":"CpG adjuvant","score":0.9620000123977661},{"id":"https://openalex.org/keywords/nanoparticle-based-vaccines","display_name":"nanoparticle vaccine","score":0.6060000061988831},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.7390000224113464},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.847000002861023},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.37599998712539673},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5680000185966492},{"id":"https://openalex.org/keywords/tumor-immunogenicity","display_name":"tumor immunogenicity","score":0.4230000078678131},{"id":"https://openalex.org/keywords/ifn-gamma-response","display_name":"IFN-gamma response","score":0.46399998664855957}],"concepts":[{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.7773439288139343},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.7574669122695923},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.6685329079627991},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.6059080958366394},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5334116816520691},{"id":"https://openalex.org/C2777807558","wikidata":"https://www.wikidata.org/wiki/Q4914764","display_name":"Biodistribution","level":3,"score":0.5234217643737793},{"id":"https://openalex.org/C2776662205","wikidata":"https://www.wikidata.org/wiki/Q2459684","display_name":"Tumor antigen","level":4,"score":0.4738738238811493},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3987104892730713},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.39202699065208435},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3486884832382202},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.32297730445861816},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28495165705680847},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.24966761469841003},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-2223","doi":"https://doi.org/10.1158/1538-7445.am2020-2223","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-2223","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3091376671","https://openalex.org/W2265709812","https://openalex.org/W3015841684","https://openalex.org/W4414934081","https://openalex.org/W2765124987","https://openalex.org/W4405700454","https://openalex.org/W2944908391","https://openalex.org/W2903067379","https://openalex.org/W994704903","https://openalex.org/W2769547311"],"abstract_inverted_index":{"Abstract":[0],"We":[1,204],"have":[2,50,86,131],"developed":[3],"a":[4,194,375,398],"novel,":[5],"non-viral":[6,36,399],"nanoparticle-based":[7,442],"vaccine":[8,46,214,407],"platform":[9,469],"that":[10,52,88,134,170,206,323,388],"has":[11,39,149,474],"shown":[12,51,87],"exciting":[13],"promise":[14],"for":[15,42,59,110,315,346,494],"cancer":[16],"antigen":[17,43,127,395,467],"delivery":[18,44,248,396,468],"to":[19,141,160,200,216,222,317,336],"increase":[20],"antigen-specific":[21],"anti-tumor":[22,136,180,211,377],"immune":[23,137,171,181,220,227,358,409,448],"responses":[24,138],"and":[25,45,66,118,123,126,154,226,233,252,282,344,348,501],"significantly":[26,263,300,402],"prolong":[27],"survival":[28,283],"in":[29,62,77,144,163,185,238,262,274,285,321,361,477],"the":[30,63,84,100,107,175,178,186,207,219,239,275,286,294,307,327,389,404,417,421,436,478,487,491],"aggressive":[31,240,479],"B16-F10":[32,241,287,330,480],"melanoma":[33,242,289,332,481],"model.":[34,244,290],"Our":[35],"protein":[37,212,400,465],"nanoparticle":[38,85,108,213,296,401,431,466],"advantageous":[40],"properties":[41],"development.":[47],"Nanoparticle":[48],"studies":[49,82],"there":[53,190],"is":[54,76,168,191,340,364,370,416],"an":[55,156],"optimal":[56],"size":[57,79],"range":[58],"passive":[60],"transport":[61],"lymphatic":[64],"system":[65,221],"uptake":[67],"by":[68,94,268],"antigen-presenting":[69],"cells":[70],"(approximately":[71],"20-45":[72],"nm);":[73],"our":[74,210,413,440],"particle":[75],"this":[78,145,339,362,368,415],"range.":[80],"Biodistribution":[81],"of":[83,97,106,113,197,209,249,293,306,357,374,391,424,427,439,486,490],"they":[89],"are":[90,139],"effectively":[91],"taken":[92],"up":[93,316],"almost":[95],"50%":[96,305],"DCs":[98],"within":[99,258],"draining":[101],"lymph":[102],"nodes.":[103],"The":[104,291,353],"structure":[105],"allows":[109],"independent":[111],"functionalization":[112],"its":[114],"internal":[115],"hollow":[116],"cavity":[117],"external":[119],"surface,":[120],"enabling":[121],"efficient":[122],"simultaneous":[124,247],"adjuvant":[125],"co-delivery.":[128],"We,":[129],"as":[130],"others,":[132],"found":[133],"vaccine-elicited":[135],"insufficient":[140],"cure":[142],"animals":[143],"model.Immune":[146],"checkpoint":[147,172,228,359,392,410,449,472],"inhibition":[148,173,360,393,473],"provided":[150],"significant":[151,195],"clinical":[152,192],"benefit":[153],"become":[155],"effective":[157],"alternative":[158],"treatment":[159],"standard":[161],"chemotherapies":[162],"some":[164],"tumor":[165,187,243,383],"types.":[166],"It":[167],"believed":[169],"releases":[174],"brake":[176],"on":[177],"existing":[179],"response;":[182],"however,":[183],"even":[184,237],"types":[188],"where":[189],"benefit,":[193],"proportion":[196],"patients":[198],"fail":[199],"achieve":[201],"long-term":[202,302],"remission.":[203],"hypothesized":[205],"combination":[208,292,311,390,425],"(\"E2\";":[215],"further":[217],"prime":[218],"specific":[223],"tumor-associated":[224],"antigens)":[225],"blockade":[229,411],"will":[230],"be":[231],"synergistic":[232,422],"yield":[234],"improved":[235],"efficacy,":[236],"Immunization":[245],"with":[246,297,310,326,342,394,429,447,471],"CpG":[250],"(adjuvant)":[251],"gp100":[253],"(melanoma":[254],"MHC-I":[255],"restricted":[256],"antigen)":[257],"E2":[259,441],"nanoparticles":[260],"results":[261],"increased":[264,301],"gp100-specific":[265],"IFN-\u03b3":[266],"production":[267],"ELISpot,":[269],"CD8":[270,278],"T":[271,279],"cell":[272,280],"count":[273],"spleen,":[276],"tumor-infiltrating":[277],"population,":[281],"time":[284],"murine":[288],"CpG-gp-E2":[295,347],"anti-PD-1":[298,349,428],"therapy":[299,312,426],"survival;":[303],"approximately":[304],"mice":[308,322],"treated":[309],"remained":[313],"tumor-free":[314],"60":[318],"days":[319],"(cure)":[320],"were":[324],"inoculated":[325],"poorly":[328],"immunogenic":[329],"syngeneic":[331],"24":[333],"hours":[334],"prior":[335],"initiating":[337],"treatment;":[338],"compared":[341],"0%":[343],"\u22485%":[345],"treatments":[350],"alone,":[351],"respectively.":[352],"very":[354],"limited":[355],"efficacy":[356,405,476],"model":[363,482],"well":[365],"documented.":[366],"Thus,":[367],"result":[369],"more":[371],"significant.":[372],"Evidence":[373],"durable":[376],"response":[378],"was":[379],"also":[380],"observed":[381],"upon":[382],"re-challenge.":[384],"These":[385,433],"investigations":[386],"show":[387],"using":[397],"improves":[403],"over":[406],"or":[408],"alone.To":[412],"knowledge,":[414],"first":[418],"report":[419],"demonstrating":[420],"effects":[423],"protein-based":[430],"vaccines.":[432],"data":[434],"support":[435],"exceptional":[437],"utility":[438],"vaccines,":[443],"especially":[444],"when":[445],"combined":[446,470],"blockade.":[450],"Citation":[451],"Format:":[452],"Jo":[453],"Anne":[454],"Tucker,":[455],"Medea":[456],"Neek,":[457],"Szu-Wen":[458],"Wang,":[459],"Edward":[460],"L.":[461],"Nelson.":[462],"A":[463],"novel":[464],"curative":[475],"[abstract].":[483],"In:":[484],"Proceedings":[485],"Annual":[488],"Meeting":[489],"American":[492],"Association":[493],"Cancer":[495,507],"Research":[496],"2020;":[497],"2020":[498],"Apr":[499],"27-28":[500],"Jun":[502],"22-24.":[503],"Philadelphia":[504],"(PA):":[505],"AACR;":[506],"Res":[508],"2020;80(16":[509],"Suppl):Abstract":[510],"nr":[511],"2223.":[512]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2020-09-11T00:00:00"}